User-Agent: Microsoft Outlook Express Macintosh Edition - 5.01 (1630)
ABSTRACT: Cancer occurrence after cosmetic breast implantation
in Denmark
[10/10/2000; International Journal of Cancer]
Most studies on cancer incidence after breast implantation have focused
on breast cancer, while the risk of cancers at other sites has
been less well investigated. We examined cancer incidence among
1,653 women who underwent cosmetic breast implant surgery at
private clinics of plastic surgery in Denmark and 1,736 women
attending the same clinics for other reasons during the period
1973-1995. Furthermore, we updated previously reported results
among 1,114 women who received implants for cosmetic indications
at public hospitals. All women were followed for cancer through
the Danish Cancer Registry. In comparison with the general female
population, the overall standardized incidence ratio (SIR) for
cancer among women who received implants in private clinics was
1.65 [95% confidence interval (CI) = 1.17-2.27]. This elevated
SIR reflected increased incidence ratios for almost all major
cancer sites; however, only for non-melanoma skin cancer was
there an excess of more than 2 cases. No significant excess of
cancer was observed among women who received implants in public
hospitals (SIR = 1.10, 95% CI = 0.76-1.52) or among women attending
the private clinics for other problems (SIR = 1.10, 95% CI =
0.78-1.52). The SIRs for breast cancer after breast implantation
were 1.1 (95% CI = 0.5-2.2) among private clinic patients and
0.9 (95% CI = 0.4-1.7) among public hospital patients. The overall
findings of these 2 implant cohorts and results from other investigations
suggest that cancer risk is probably not increased among women
receiving cosmetic breast implants. The inconsistent results
for private clinics and public hospitals are likely related to
selection bias and confounding among the private clinic patients,
but our data did not permit exploration of these possibilities.
Further research into the determinants of these inconsistencies
is warranted.
Int. J. Cancer 88:301-306, 2000.
The full article can be found at:
http://www3.interscience.wiley.com/cgi-bin/abstract/73500336/START
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
